Wang, Hui

No ORCID on file · 15 papers in corpus · active 2021-2024

Study types

  • other 10
  • article 5

Condition tags

  • endometriosis 12
  • endometrioma 4
  • dysmenorrhea 2
  • infertility 2
article 2024
·doi:10.6084/m9.figshare.26693698

Supplementary Material 5.

other 2023
·doi:10.6084/m9.figshare.c.6579136

Abstract Background Endometriosis (EMS) is a “tumour-like” gynaecological disease with distant metastasis, and studies have shown that EMS can induce distant metastasis through vascular vessels, but the driving factors and their mechanism a…

other 2023
·doi:10.6084/m9.figshare.c.6579136.v1

Abstract Background Endometriosis (EMS) is a “tumour-like” gynaecological disease with distant metastasis, and studies have shown that EMS can induce distant metastasis through vascular vessels, but the driving factors and their mechanism a…

article 2022
·doi:10.6084/m9.figshare.17870091

Additional file 1. Clinical parameters in women with endometrioma-associated subfertility.

article 2022
·doi:10.6084/m9.figshare.17870091.v1

Additional file 1. Clinical parameters in women with endometrioma-associated subfertility.

other 2022
·doi:10.6084/m9.figshare.c.5777823.v1

Abstract Background Intrauterine insemination (IUI) treatment is recommended in subfertile women with AFS/ASRM stage I/II endometriosis. However, the efficacy of IUI in women with ovarian endometriomas with tubal patency is uncertain. We ex…

other 2022
·doi:10.6084/m9.figshare.c.5777823

Abstract Background Intrauterine insemination (IUI) treatment is recommended in subfertile women with AFS/ASRM stage I/II endometriosis. However, the efficacy of IUI in women with ovarian endometriomas with tubal patency is uncertain. We ex…

article 2021
·doi:10.6084/m9.figshare.14795093

Additional file 1: Supplemental Table 1. Endometriosis Health Profile-30 at month 3 – pain; Supplemental Table 2. Endometriosis Health Profile-30 at month 3 – control and powerlessness; Supplemental Table 3. Endometriosis Health Profile-30 …

article 2021
·doi:10.6084/m9.figshare.14795093.v1

Additional file 1: Supplemental Table 1. Endometriosis Health Profile-30 at month 3 – pain; Supplemental Table 2. Endometriosis Health Profile-30 at month 3 – control and powerlessness; Supplemental Table 3. Endometriosis Health Profile-30 …

other 2021
·doi:10.6084/m9.figshare.16862881.v1

Additional file 1.

other 2021
·doi:10.6084/m9.figshare.16862881

Additional file 1.

other 2021
·doi:10.6084/m9.figshare.c.5470895

Abstract Background Elagolix is an oral, gonadotropin-releasing hormone (GnRH) receptor antagonist, that significantly reduces dysmenorrhea and non-menstrual pelvic pain (NMPP) in women with moderate to severe endometriosis-associated pain.…

other 2021
·doi:10.6084/m9.figshare.c.5470895.v1

Abstract Background Elagolix is an oral, gonadotropin-releasing hormone (GnRH) receptor antagonist, that significantly reduces dysmenorrhea and non-menstrual pelvic pain (NMPP) in women with moderate to severe endometriosis-associated pain.…

other 2021
·doi:10.6084/m9.figshare.c.5675536

Abstract Background Endometriosis, the presence of active endometrial tissue outside the lining membrane of the uterine cavity, is a common disease in women of childbearing age. The ectopic endometrium has some characteristics of tumor tiss…

other 2021
·doi:10.6084/m9.figshare.c.5675536.v1

Abstract Background Endometriosis, the presence of active endometrial tissue outside the lining membrane of the uterine cavity, is a common disease in women of childbearing age. The ectopic endometrium has some characteristics of tumor tiss…